Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The investigators propose a study to evaluate the safety, local tolerability, convenience,
and efficacy of self-administered Icatibant for the treatment of acute attacks of hereditary
angioedema. The investigators believe that self administration with Icatibant for treatment
of an acute attack of angioedema will not change the time to complete or near complete
resolution of symptoms compared to treatment with Icatibant in a medical facility.